Advertisement
Advertisement
U.S. Markets open in 1 hr 25 mins
Advertisement
Advertisement
Advertisement
Advertisement

Surface Oncology, Inc. (SURF)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.8800-0.0800 (-4.08%)
At close: 04:00PM EDT
1.8701 -0.01 (-0.53%)
Pre-Market: 08:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9600
Open1.9500
Bid1.8700 x 1800
Ask1.9800 x 800
Day's Range1.8800 - 1.9800
52 Week Range1.8600 - 9.5700
Volume477,920
Avg. Volume762,478
Market Cap86.734M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-1.7740
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.40
  • Simply Wall St.

    Bullish: Analysts Just Made A Substantial Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

    Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders will have a reason to smile today, with the analysts making...

  • GlobeNewswire

    Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022

    – Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through ATM facility – – Expanding open label lead-in for SRF388 in first-line hepatocellular carcinoma (HCC), with initial data expected in the first half of 2023 – – New SRF388 clinical data to be presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) --

  • GlobeNewswire

    Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to five new employees to purchase an aggregate of 50,000 shares of the company’s common stock with a per share exercise price of $2.33, the closing price of Surface’s common stock as reported by Nasdaq on May 2, 2022.

Advertisement
Advertisement